Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056159 · ClinicalTrials.gov registry record · Phase 1
A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT01056159 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 47 participants.
The verdict
NCT01056159, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The study will measure the improvement in lung function in subjects with asthma after inhaling from two inhalers, Albuterol in a dry powder inhaler and albuterol in an HFA (hydrofluoroalkane), metered dose inhaler.
Interventions
- DRUG Albuterol dry powder inhaler
- DRUG Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01056159
The ClinicalTrials.gov registry entry for NCT01056159 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albuterol dry powder inhaler is the first listed.
NCT01056159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01056159 about?
NCT01056159 is a clinical study titled "A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)". The study will measure the improvement in lung function in subjects with asthma after inhaling from two inhalers, Albuterol in a dry powder inhaler and albuterol in an HFA (hydrofluoroalkane), metered dose inhaler.
What is the current status of trial NCT01056159?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT01056159?
The interventions under investigation include: Albuterol dry powder inhaler (DRUG), Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) (DRUG).
Who is sponsoring clinical trial NCT01056159?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.